View Filing Data

$ 1,241

$ 567

$ 779

$ 928

$ 758

$ 982

$ 2,547

$ 701

$ 3,515

$ 4,988

Grant Revenue [Member]

Royalties From Product Sales and License Fees [Member]

2,037

3,572

^[1]

Subscription and Advertisement Revenues [Member]

1,221

392

^[1]

Sale of Research Products and Services [Member]

^[2]

691

^[1]

$ 257

$ 333

^[1]

[1]

Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.

[2]

These revenues were generated by LifeMap Sciences, which is a subsidiary of AgeX, are included in Lineage consolidated revenues for the period from January 1, 2018 through August 29, 2018, the date immediately preceding the AgeX Deconsolidation. As a result of the AgeX Deconsolidation on August 30, 2018, Lineage does not expect to recognize subscription and advertisement revenues during subsequent accounting periods.

Summary of Significant Accounting Policies - Schedule of Disaggregated by Geographical Revenue (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

$ 1,241

$ 567

$ 779

$ 928

$ 758

$ 982

$ 2,547

$ 701

$ 3,515

$ 4,988

United States [Member]

2,092

1,804

Foreign [Member]

Outstanding Asterias common stock

^[1]

$ 1,423

$ 3,184

[1]	Foreign revenues are primarily generated from grants in Israel.

Asterias Merger (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 08, 2019	Apr. 30, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	May 13, 2016
Closing price of common stock				$ 93,840	$ 112,959	$ 93,840
Fair value of warrants			$ 372
Common stock held in investment		2,621,811
Share price, per share		$ 1.31			$ 0.62
Fair value of equity method investment, shares	21,700,000
Fair value of equity method investment, value		$ 20,200		$ 13,500		13,500
Fair value calculation, description		The fair value of the Asterias shares was approximately $20.2 million as of March 8, 2019, the closing date of the Asterias Merger, based on $0.93 per share, which was calculated by multiplying (a) $1.31, the closing price of Lineage common shares on such date by (b) the Merger Exchange Ratio.
Maximum [Member]
Intangible asset, useful life					10 years
Minimum [Member]
Intangible asset, useful life					5 years
December 31, 2018 to March 8, 2019 [Member]
Unrealized loss					$ 6,700
December 31, 2017 to December 31, 2018 [Member]
Unrealized loss						$ 35,400
December 31, 2017 to December 31, 2018 [Member] \| Maximum [Member]
Share price, per share				$ 2.25		$ 2.25
December 31, 2017 to December 31, 2018 [Member] \| Minimum [Member]
Share price, per share				$ 0.62		$ 0.62
General and Administrative Expense [Member]
Acquisition related costs					$ 5,100
Common Stock [Member]
Number of warrants issued to purchase of common stock							2,959,559
Exercise price							$ 4.37
Warrant term							5 years
Warrant expiration date							May 13, 2021
Asterias Warrants [Member]
Number of warrants issued to purchase of common stock							2,813,159
Lineage Warrants [Member]
Number of warrants issued to purchase of common stock					1,089,900
Exercise price					$ 6.15
Warrant expiration date					May 13, 2021
Fair value of warrants	$ 495
AST Clinical Program [Member]
Identifiable intangible asset acquired		$ 46,500
Royalty Contracts [Member]
Intangible asset, useful life					5 years
In Process Research and Development [Member]
Identifiable intangible asset acquired		31,700
CIRM [Member]
Identifiable intangible asset acquired		$ 14,800
Parent Company [Member]
Fair value of warrants			$ 332
Exchange of shares			251,835
Exchange for cash			$ 40
Asterias [Member]
Upfront payment received				$ 1,000
Estimated purchase price				$ 200
Merger Consideration [Member] \| Parent Company [Member]
Stock-for-stock transaction		24,695,898
Closing price of common stock		$ 32,400
Merger Consideration [Member] \| Asterias [Member]
Stock-for-stock transaction		0.71
Merger Consideration [Member] \| Asterias [Member] \| Restricted Stock [Member]
Stock-for-stock transaction		58,085

Asterias Merger - Schedule of Merger Consideration Transferred (Details) - Asterias Biotherapeutics, Inc. [Member]
$ / shares in Units, $ in Thousands

Mar. 08, 2019

USD ($)

$ / shares

56,530,902

^[1]

Exchange ratio

0.710

Lineage common shares issuable

40,136,672

Per share price of Lineage common shares | $ / shares

$ 1.31

Purchase price | $

$ 52,580

Shareholders Other than Lineage [Member]

Outstanding Asterias common stock

34,783,333

^[1]

Exchange ratio

0.710

Lineage common shares issuable

24,695,898

^[2]

Per share price of Lineage common shares | $ / shares

$ 1.31

Purchase price | $

$ 32,353

Parent Company [Member]

Outstanding Asterias common stock

21,747,569

Exchange ratio

0.710

Lineage common shares issuable

15,440,774

^[3]

Per share price of Lineage common shares | $ / shares

$ 1.31

Purchase price | $

$ 20,227

^[3]

[1]	Includes 81,810 shares of Asterias restricted stock unit awards that immediately vested on March 8, 2019 and converted into the right to receive common shares of Lineage based on the Merger Exchange Ratio, resulting in 58,085 common shares of Lineage issued on March 8, 2019 as part of the Merger Consideration. These restricted stock units were principally attributable to pre-combination services and included as part of the purchase price in accordance with ASC 805. See Note 12 for Asterias restricted stock units that vested on the closing of the Asterias Merger attributable to post-combination services that were recorded outside of the purchase price as an immediate charge to stock-based compensation expense.
[2]	Net of a de minimis number of fractional shares which were paid in cash.
[3]	Estimated fair value for Lineage's previously held 38% ownership interest in Asterias common stock is part of the total purchase price of Asterias for purposes of the purchase price allocation under ASC 805 and for Lineage's adjustment of its 38% interest to fair value at the effective date of the Asterias Merger and immediately preceding the consolidation of Asterias' results with Lineage. No actual common shares of Lineage were issued to Lineage in connection with the Asterias Merger.

Asterias Merger - Schedule of Merger Consideration Transferred (Details) (Parenthetical) - shares	Mar. 08, 2019	Jul. 10, 2017
Ownership interest		99.80%
Asterias Biotherapeutics, Inc. [Member] \| Parent Company [Member]
Number of shares issued	58,085
Ownership interest	38.00%
Asterias Biotherapeutics, Inc. [Member] \| Restricted Stock [Member]
Number of restricted stock vested	81,810

Asterias Merger - Schedule of Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Estimated goodwill (c-a-b)

^[1]

$ 10,672

Asterias Biotherapeutics, Inc. [Member]

Cash and cash equivalents

3,117

Prepaid expenses and other assets, current and noncurrent

660

Machinery and equipment

308

Long-lived intangible assets - royalty contracts

650

Acquired in-process research and development ("IPR&D")

46,540

Total assets acquired

51,275

Accrued liabilities and accounts payable

982

Liability classified warrants

867

Deferred license revenue

200

Long-term deferred income tax liability

10,753

Total liabilities assumed

12,802

Net assets acquired, excluding goodwill (a)

38,473

Fair value of Lineage common shares held by Asterias (b)

3,435

Total purchase price (c)

52,580

Estimated goodwill (c-a-b)

$ 10,672

[1]	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3).

Asterias Merger - Schedule of Valuation of Identifiable Intangible Assets and Their Estimated Useful Lives (Details) - Asterias Biotherapeutics, Inc. [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Preliminary Estimated Asset Fair Value	$ 47,190
In Process Research and Development [Member]
Preliminary Estimated Asset Fair Value	$ 46,540
Useful Life (Years)	0 years
Royalty Contracts [Member]
Preliminary Estimated Asset Fair Value	$ 650
Useful Life (Years)	5 years

Accounting for Common Stock of Oncocyte, at Fair Value (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	Sep. 11, 2019	Sep. 10, 2019	Jul. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 08, 2019	Jul. 10, 2017
Ownership percentage							99.80%
Closing price per share				$ 0.62		$ 1.31
Unrealized gain on marketable equity securities				$ (2,898)	$ 1,158
OncoCyte Corporation [Member]
Number of stock sold	4,000,000		2,250,000
Number of stock sold, value	$ 6,500		$ 4,200
Ownership percentage	16.00%	24.00%		28.00%
Reduction in ownership percentage				24.00%
Number of shares owned				8,400,000	14,700,000
Fair value on investment				$ 19,000	$ 20,300
Closing price per share				$ 2.25	$ 1.38
Realized gain on equity method investment				$ 546
Unrealized gain on equity method investment		$ 8,000		$ 8,001	$ (47,985)
Unrealized gain on marketable equity securities		$ 800

Sale of Significant Ownership Interest in AgeX to Juvenescence Limited (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Nov. 02, 2018	Aug. 30, 2018	Dec. 31, 2019	Nov. 28, 2018
Parent Company [Member] \| Common Stock [Member]
Number of share sold			765,889
Number of shares owned			1,000,000	1,700,000
Common stock shares issued and outstanding percentage				4.80%
Juvenescence Limited [Member]
Number of share sold		14,400,000
Stock Purchase Agreement [Member] \| Juvenescence Limited [Member]
Number of share sold		14,400,000
Sale of stock price per share		$ 3.00
Purchase price of shares		$ 43,200
Purchase price amount paid	$ 10,800
Indemnity cap		4,300
Proceeds from public offering		$ 50,000
Stock Purchase Agreement [Member] \| Juvenescence Limited [Member] \| Series A Preferred Share [Member]
Debt conversion, price per share		$ 15.60
Stock Purchase Agreement [Member] \| Juvenescence Limited [Member] \| Promissory Note [Member]
Purchase price amount paid		$ 21,600
Debt instrument interest rate		7.00%
Debt instrument maturity term		2 years
Debt instrument maturity date		Aug. 30, 2020
Interest income debt			$ 1,500
Promissory Note principal and accrued interest			$ 23,600
Stock Purchase Agreement [Member] \| Juvenescence Limited [Member] \| Closing of Transaction [Member]
Purchase price amount paid		$ 10,800
Shareholder Agreement [Member]
Shareholder agreement description		Lineage and Juvenescence entered into a Shareholder Agreement, dated August 30, 2018, setting forth the governance, approval and voting rights of the parties with respect to their holdings of AgeX common stock, including rights of representation on AgeX's board of directors, approval rights, preemptive rights, rights of first refusal and co-sale and drag-along and tag-along rights for so long as either Lineage or Juvenescence continue to own at least 15% of the outstanding shares of AgeX common stock.

Deconsolidation and Distribution of AgeX (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Nov. 28, 2018	Aug. 30, 2018	Dec. 31, 2019	Nov. 29, 2018
Common Stock [Member]
Common shares issued			93,000
AgeX Therapeutics, Inc. [Member]
Gain on deconsolidation			$ 78,500
Gain on sale of shares			$ 39,200
Parent Company [Member]
Percentage of ownership before transaction		80.40%
Percentage of ownership after transaction		40.20%
Parent Company [Member] \| Common Stock [Member]
Number of share sold			765,889
Number of shares owned	1,700,000		1,000,000
Number of share sold, value			$ 1,800
Percentage of outstanding common stock			2.50%
Parent Company [Member] \| Prorata Basis [Member]
Common stock, ratio description	One share of AgeX common stock for every 10 Lineage common shares owned.
Parent Company [Member] \| Prorata Basis [Member] \| Common Stock [Member]
Common shares issued	12,700,000
Dividend-in-kind	$ 34,400
Price per share				$ 2.71
Juvenescence Limited [Member]
Number of share sold		14,400,000
Percentage of ownership before transaction		5.60%
Percentage of ownership after transaction		45.80%

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Financing leases related to property and equipment	$ 96	$ 146
Depreciation and amortization expense	1,002	1,081
Proceeds from sale of equipment	209
Gain on sale of equipment	109
Gain on sale of non-capitalized assets	337
Construction in progress		1,268
Cell Cure Neurosciences, Ltd. [Member]
Construction in progress		$ 1,300

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Dec. 31, 2018

Accumulated depreciation and amortization

$ (4,591)

$ (3,185)

Property and equipment, net

8,175

4,567

Construction in progress

1,268

Property, plant and equipment, net, and construction in progress

8,175

5,835

Equipment, Furniture and Fixtures [Member]

Property and equipment, gross

4,148

3,842

Leasehold Improvements [Member]

Property and equipment, gross

2,862

3,910

Right-of-Use Assets [Member]

Property and equipment, gross

^[1]

$ 5,756

[1]	Lineage adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities see Notes 2 and 14.

Goodwill and Intangible Assets, Net (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization of intangible assets	$ 1,998	$ 2,192
Minimum [Member]
Intangible asset, useful life	5 years
Maximum [Member]
Intangible asset, useful life	10 years

Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets, Net (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Dec. 31, 2018

Goodwill

^[1]

$ 10,672

Other

66,143

19,020

Accumulated amortization

(17,895)

(15,895)

Intangible assets, net

48,248

3,125

IPR&D - OPC1 [Member]

^[2]

31,700

IPR&D - VAC2 [Member]

^[2]

14,840

Patents [Member]

Royalty Contracts [Member]

18,953

19,010

Stock Option Plan of 2012 [Member]

^[2]

$ 650

[1]	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3).
[2]	See Note 3 for information on the Asterias Merger which was consummated on March 8, 2019.

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 1,216
2021	210
2022	130
2023	130
2024	22
Total	$ 48,248	$ 3,125

Accounts Payable and Accrued Liabilities (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Separation payments	$ 700
Accrued compensation	$ 1,549	$ 2,456
Description of termination plan	Termination dates for these individuals range from August 9, 2019 to September 30, 2019.
Asterias Biotherapeutics, Inc. [Member]
Separation payments	$ 500
Description of termination plan	Termination dates for these individuals ranged from May 31, 2019 to June 28, 2019.
Asterias Biotherapeutics, Inc. [Member] \| General and Administrative Expense [Member]
Accrued compensation	$ 2,000
Asterias Biotherapeutics, Inc. [Member] \| Three Employees Member [Member]
Separation payments	$ 2,000

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 2,427	$ 2,359
Accrued liabilities	1,246	1,639
Accrued compensation	1,549	2,456
Other current liabilities	4	9
Total	$ 5,226	$ 6,463

Related Party Transactions (Details Narrative)	1 Months Ended				12 Months Ended
Related Party Transactions (Details Narrative)	Jan. 31, 2020 shares	Dec. 31, 2019 ft² shares	Jul. 31, 2019 shares	Apr. 30, 2019 shares	Dec. 31, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)	Feb. 28, 2018 USD ($) $ / shares shares
Office Space in New York City [Member]
Rent per month \| $					$ 5,050
Area of office space square feet \| ft²		900			900
AgeX Therapeutics, Inc. [Member]
Warrants to purchase of shares \| shares							248,600
Warrant exercise price share \| $ / shares							$ 2.50
AgeX Therapeutics, Inc. [Member] \| Alfred D. Kingsley [Member]
Warrant exercise price share \| $ / shares							$ 0.50
Warrants value \| $							$ 124,300
Broadwood Partners, L.P [Member]
Shares issued for settlement of warrants in connection with merger \| shares				251,835
Number of shares issued \| shares		2,000,000	1,000,000
Broadwood Partners, L.P [Member] \| Subsequent Event [Member]
Number of shares issued \| shares	623,090
Broadwood Partners, L.P [Member] \| Neal Bradsher [Member]
Legal expenses \| $					$ 221,000
OncoCyte Corporation and AgeX Therapeutics Inc [Member]
Markup rate on allocated costs					5.00%
Term of payment					30 days
Interest rate charged on unpaid and overdue invoices					15.00%
OncoCyte Corporation [Member]
Receivable from affiliates \| $						$ 2,100,000

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total use fees	$ 2,176	$ 2,168
Research and Development [Member]
Total use fees	1,286	1,378
General and Administrative Expense [Member]
Total use fees	$ 890	$ 790

Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		10 Months Ended	12 Months Ended
	Jul. 10, 2017	May 31, 2018	Jul. 31, 2017	Oct. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Apr. 30, 2017	May 13, 2016
Preferred shares, shares authorized					2,000,000	2,000,000
Preferred shares, shares issued
Preferred shares, shares outstanding
Common stock, shares authorized					250,000,000	250,000,000
Common stock, no par value
Common stock, issued					149,804,000	127,136,000
Common stock, outstanding					149,804,000	127,136,000
Number of common stock issued value					$ 103
Ownership percentage	99.80%
Noncash expense/gain					3,580	$ 5,402
Other Long-term Liabilities [Member]
Noncash expense/gain					$ 300	400
Asterias Biotherapeutics, Inc. [Member]
Warrants issued to purchase ordinary shares					1,089,900
Warrants exercisable term					30 days
Warrants exercise price per share					$ 6.15
Warrant expiration date					May 13, 2021
Unrealized gain on warrants					$ 476
Asterias Biotherapeutics, Inc. [Member] \| Long-term Liabilities [Member]
Fair value of warrant					20
Hadasit Bio-Holdings, Ltd [Member]
Common shares issued	1,220,207
Number of common stock issued value	$ 3,800
Teva Pharmaceutical Industries, Ltd [Member]
Common shares issued	927,673
Number of common stock issued value	$ 2,800
Cell Cure Neurosciences, Ltd. [Member]
Ownership percentage	62.50%
Cell Cure Warrants [Member]
Noncash expense/gain					$ 100	400
Cell Cure Warrants [Member] \| Consultants [Member]
Warrants issued to purchase ordinary shares					13,738
Warrants expiring period, description					Expire in October 2020 and January 2024
Hadasit Bio-Holdings, Ltd [Member]
Ownership percentage, non-controlling owners	21.20%
Warrants issued to purchase ordinary shares			24,566
Warrants exercisable term			5 years
Warrants exercise price per share			$ 40.5359
Teva Pharmaceutical Industries, Ltd [Member]
Ownership percentage, non-controlling owners	16.10%
Maximum [Member] \| Cell Cure Warrants [Member] \| Consultants [Member]
Warrants exercise price per share					$ 40.00
Minimum [Member] \| Cell Cure Warrants [Member] \| Consultants [Member]
Warrants exercise price per share					$ 32.02
Cantor Fitzgerald & Co [Member]
Percentage of commission payable					3.00%
Cantor Fitzgerald & Co [Member] \| Sales Agreement [Member]
Share value available for sale					$ 24,100
Cantor Fitzgerald & Co [Member] \| Maximum [Member] \| Sales Agreement [Member]
Aggregate offering price								$ 25,000
Cell Cure Neurosciences, Ltd. [Member]
Charge to equity, value							$ 10,100
Proportional transfer of carrying value						$ 1,900	$ 3,500
Number of stock options exercised to purchase ordinary shares				4,400
Cell Cure Neurosciences, Ltd. [Member] \| Hadasit Bio-Holdings, Ltd [Member]
Common shares issued		937
Purchase price, per share		$ 40.5359
Cell Cure Neurosciences, Ltd. [Member] \| Teva Pharmaceutical Industries, Ltd [Member]
Common shares issued		937
Purchase price, per share		$ 40.5359
Cell Cure Neurosciences, Ltd. [Member] \| Maximum [Member]
Ownership percentage		99.00%		98.80%
Cell Cure Neurosciences, Ltd. [Member] \| Minimum [Member]
Ownership percentage		98.80%		99.80%
Common Stock [Member]
Restricted stock, shares issued net of shares for tax withholdings					189,000	270,000
Common shares issued					93,000
Number of common stock issued value					$ 103
Warrants issued to purchase ordinary shares									2,959,559
Warrants exercise price per share									$ 4.37
Warrant expiration date									May 13, 2021

Stock-Based Awards (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Noncash stock-based compensation expense		$ 298,000
Stock-based compensation	$ 3,580	5,402
RSUs [Member]
Noncash stock-based compensation expense	$ 300	1,200
Stock-based compensation		$ 1,000
2012 Equity Incentive Plan [Member]
Number of shares available for grant			2,500,000
Weighted average fair value of stock option awards granted	$ 0.68	$ 1.24
2012 Equity Incentive Plan [Member] \| Employees [Member]
Employee withholding taxes in exchange vesting restricted stock units	$ 100	$ 200
Employee withholding taxes in exchange vesting restricted stock units, shares	109,000	134,000
2012 Equity Incentive Plan [Member] \| Maximum [Member]
Number of shares available for grant	24,000,000
Options granted term	10 years
2012 Plan [Member]
Options outstanding,weighted-average remaining contractual term	6 years 1 month 6 days
Options exercisable,weighted-average remaining contractual term	4 years 8 months 12 days
Options outstanding,intrinsic value	$ 23
Options exercisable,intrinsic value	$ 0
Asterias 2013 Equity Incentive Plan [Member]
Number of shares available for grant	7,309,184	5,189,520
Options outstanding,weighted-average remaining contractual term	9 years 2 months 12 days
Options outstanding,intrinsic value	$ 0
Number of restricted stock units	84,940
Common shares issued	60,304
Lineage's 2002 Plan and 2012 Equity Incentive Plan [Member]
Unrecognized compensation costs related to unvested stock options	$ 4,100
Expected recognized expense over weighted average period	2 years 6 months

Stock-Based Awards - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) - $ / shares

10 Months Ended

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares Available for Grant, Beginning balance

1,885

2,485

Shares Available for Grant, Board mandated restriction restored

^[1]

5,000

Shares Available for Grant, Exchange of options with Cell Cure

^[2]

(866)

Shares Available for Grant, Restricted stock units granted

^[3]

(1,586)

Shares Available for Grant, Inducement option grant

^[4]

Shares Available for Grant, Options granted

(3,581)

(1,559)

Shares Available for Grant, Options forfeited

2,736

731

Shares Available for Grant, Adjustment due to the AgeX Distribution

^[5]

117

(2,294)

Shares Available for Grant, Adjustment to inducement options due to the AgeX Distribution

^[5]

Shares Available for Grant, Adjustment to restricted stock units due to the AgeX Distribution

^[5]

(272)

Shares Available for Grant, Restricted stock units vested

Shares Available for Grant, Restricted stock units expired unvested

246

Shares Available for Grant, Increase to the 2012 Plan

8,000

Shares Available for Grant, Ending balance

9,157

1,885

Number of Options Outstanding, Beginning balance

13,867

8,043

Number of Options Outstanding, Board mandated restriction restored

^[1]

Number of Options Outstanding, Exchange of options with Cell Cure

^[2]

866

Number of Options Outstanding, Restricted stock units granted

^[3]

Number of Options Outstanding, Inducement option grant

^[4]

1,500

Number of Options Outstanding, Options granted

3,581

1,559

Number of Options Outstanding, Options forfeited

(2,736)

(750)

Number of Options Outstanding, Adjustment due to the AgeX Distribution

^[5]

(2)

2,294

Number of Options Outstanding, Adjustment to inducement options due to the AgeX Distribution

^[5]

355

Number of Options Outstanding, Adjustment to restricted stock units due to the AgeX Distribution

^[5]

Number of Options Outstanding, Restricted stock units vested

Number of Options Outstanding, Restricted stock units expired unvested

Number of Options Outstanding, Increase to the 2012 Plan

Number of Options Outstanding, Ending balance

14,710

13,867

Number of Options Outstanding, Options exercisable

9,555

Number of RSUs Outstanding, Beginning balance

402

Number of RSUs Outstanding, Board mandated restriction restored

^[1]

Number of RSUs Outstanding, Exchange of options with Cell Cure

^[2]

Number of RSUs Outstanding, Restricted stock units granted

^[3]

793

Number of RSUs Outstanding, Inducement option grant

^[4]

Number of RSUs Outstanding, Options granted

Number of RSUs Outstanding, Options forfeited

Number of RSUs Outstanding, Adjustment due to the AgeX Distribution

^[5]

Number of RSUs Outstanding, Adjustment to inducement options due to the AgeX Distribution

^[5]

Number of RSUs Outstanding, Adjustment to restricted stock units due to the AgeX Distribution

^[5]

136

Number of RSUs Outstanding, Restricted stock units vested

(239)

(466)

Number of RSUs Outstanding, Restricted stock units expired unvested

(123)

Number of RSUs Outstanding, Increase to the 2012 Plan

Number of RSUs Outstanding, Ending balance

166

402

Weighted Average Exercise Price of Options Outstanding, beginning balance

$ 2.44

$ 3.38

Weighted Average Exercise Price of Options Outstanding, Exchange of options with Cell Cure

^[2]

2.16

Weighted Average Exercise Price of Options Outstanding, Inducement option grant

^[4]

2.31

Weighted Average Exercise Price of Options Outstanding, Options granted

1.06

2.84

Weighted Average Exercise Price of Options Outstanding, Options forfeited

2.13

3.33

Weighted Average Exercise Price of Options Outstanding, Adjustment due to the AgeX Distribution

^[5]

Weighted Average Exercise Price of Options Outstanding, Adjustment to inducement options due to the AgeX Distribution

^[5]

Weighted Average Exercise Price of Options Outstanding, Adjustment to restricted stock units due to the AgeX Distribution

^[5]

Weighted Average Exercise Price of Options, Restricted stock units vested

Weighted Average Exercise Price of Options Outstanding, Restricted stock units expired unvested

Weighted Average Exercise Price of Options Outstanding, Increase to the 2012 Plan

Weighted Average Exercise Price of Options Outstanding, end balance

$ 2.17

2.17

$ 2.44

Weighted Average Exercise Price of Options Outstanding, Options exercisable

$ 2.54

Asterias 2013 Equity Incentive Plan [Member] | Asterias Biotherapeutics, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares Available for Grant, Beginning balance

5,190

Shares Available for Grant, Options granted

(490)

Shares Available for Grant, Options forfeited

140

Shares Available for Grant, Ending balance

4,840

Number of Options Outstanding, Beginning balance

Number of Options Outstanding, Options granted

490

Number of Options Outstanding, Options forfeited

(140)

Number of Options Outstanding, Ending balance

350

Number of Options Outstanding, Options exercisable

Number of RSUs Outstanding, Beginning balance

Number of RSUs Outstanding, Options granted

Number of RSUs Outstanding, Options forfeited

Number of RSUs Outstanding, Ending balance

Weighted Average Exercise Price of Options Outstanding, beginning balance

Weighted Average Exercise Price of Options Outstanding, Options granted

1.59

Weighted Average Exercise Price of Options Outstanding, Options forfeited

1.63

Weighted Average Exercise Price of Options Outstanding, end balance

1.57

$ 1.57

Weighted Average Exercise Price of Options Outstanding, Options exercisable

[1]	On October 13, 2017, Lineage's Board of Directors determined to temporarily set a 5.0 million total share limit on shares available for the grant of share-based awards pursuant to the 2012 Plan. As of December 31, 2017, the total 2.5 million shares available for grant was net of this 5.0 million share restriction. On May 4, 2018, Lineage's Board of Directors removed this restriction, thereby increasing shares available for the grant of share-based awards pursuant to the 2012 Plan.
[2]	On July 9, 2018, Lineage's Board of Directors terminated the Cell Cure Equity Incentive Plan (the "Cell Cure Plan"), under which Cell Cure employees and certain consultants ("Cell Cure Option Holders") held outstanding options to purchase shares of common stock in Cell Cure, and Lineage granted the Cell Cure Option Holders Lineage options of equivalent value under the 2012 Plan in exchange for their Cell Cure options (the "Lineage Exchange"). The Lineage Exchange resulted in 866,000 grants of Lineage stock options under the 2012 Plan, all issued with an exercise price of $2.16 per share to the Cell Cure Option Holders, based on Lineage's closing stock price on July 9, 2018. Of the total options granted under the Lineage Exchange, 275,000 are subject to continued service-based vesting from the original terms under the Cell Cure Plan, and 591,000 were immediately vested on the exchange date to reflect the fact that the Cell Cure Options Holders held prior to the exchange were already vested. Equivalent value of the Lineage Exchange was determined using the Black-Scholes option pricing model. The Lineage Exchange was accounted for as a modification under ASC 718, and Lineage recorded a noncash stock-based compensation expense of $298,000 for the year ended December 31, 2018 included in consolidated stock-based compensation expense.
[3]	On May 24, 2018 and August 10, 2018, Lineage granted 485,000 and 8,000 RSUs, respectively, to employees. The RSUs vest in increments upon the attainment of specified performance conditions, as determined by Lineage's Board of Directors, including the completion of the AgeX Distribution and certain clinical milestones in the development of OpRegen and Renevia. Stock-based compensation expense for these performance-based RSUs is recognized when it is probable that the respective milestone will be achieved, as determined by Lineage's Board of Directors. On October 4, 2018, Lineage's Board of Directors determined that Lineage had achieved the AgeX Distribution performance condition and as a result 25%, or 123,250, of the RSUs granted in May and August 2018 vested. On December 18, 2018, Lineage's Board of Directors determined that Lineage had achieved other milestones related to the RSUs and as a result an additional 50%, or 246,500, of the RSUs granted in May and August 2018 vested. The remaining 25%, or 123,250 RSUs, expired unvested on December 31, 2018. On September 17, 2018, Lineage granted Lineage's new President and Chief Executive Officer, Brian M. Culley, two RSU awards under the 2012 Plan: (1) an award of 200,000 restricted stock units ("RSU Award No. 1") and (2) an award of 100,000 restricted stock units ("RSU Award No. 2" and together with RSU Award No. 1, the "RSU Awards"). Subject to Mr. Culley's continued service with Lineage, 25% of the shares subject to RSU Award No. 1 will vest on the first anniversary of the date of grant, and the balance of the shares subject to RSU Award No. 1 will vest in 12 equal quarterly installments at the end of each quarter thereafter. RSU Award No. 2 vested in full on January 1, 2019.
[4]	On September 17, 2018 (the "Start Date"), Brian M. Culley became President and Chief Executive Officer of Lineage. In connection with Mr. Culley's employment, Lineage granted Mr. Culley an inducement option to purchase 1,500,000 of Lineag's common shares (the "Culley Option"). The exercise price of the Culley Option is $2.31 per share, which was the closing stock price on September 17, 2018. This grant was made outside of the 2012 Plan and was approved by the independent members of the Board of Directors. Subject to Mr. Culley's continued service with Lineage on the applicable vesting date, the Culley Option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the Start Date, and the balance of the Culley Option will vest and become exercisable in 36 equal monthly installments thereafter.
[5]	Reflects the equitable adjustment to the exercise prices and number of outstanding stock options, and to restricted stock units, necessary to maintain the intrinsic value of those awards immediately prior to and following the AgeX Distribution.

Stock-Based Awards - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Thousands							12 Months Ended
	Dec. 18, 2018	Oct. 04, 2018	Sep. 17, 2018	Aug. 10, 2018	May 24, 2018	Dec. 31, 2017	Dec. 31, 2018	Jul. 09, 2018	Oct. 13, 2017
Number of option vested	246,500	123,250					123,250
Noncash stock-based compensation expense							$ 298,000
Performance-based vesting description	On December 18, 2018, BioTime's Board of Directors determined that BioTime had achieved other milestones related to the RSUs and as a result an additional 50%, or 246,500, of the RSUs granted in May and August 2018 vested.	On October 4, 2018, BioTime's Board of Directors determined that BioTime had achieved the AgeX Distribution performance condition and as a result 25%, or 123,250, of the RSUs granted in May and August 2018 vested.					The remaining 25%, or 123,250 RSUs, expired unvested on December 31, 2018.
2012 Equity Incentive Plan [Member]
Number of shares available for grant						2,500,000
Number of shares repurchased						5,000,000
Board of Directors [Member] \| 2012 Equity Incentive Plan [Member]
Number of shares available for grant									5,000,000
Cell Cure Option Holders [Member]
Number of option vested								591,000
Cell Cure Option Holders [Member] \| 2012 Equity Incentive Plan [Member]
Number of shares available for grant								866,000
Exercise price per share								$ 2.16
Number of option vested								275,000
Employees [Member] \| 2012 Equity Incentive Plan [Member]
Number of restricted stock units grant				8,000	485,000
Restricted stock units expiration date					Dec. 31, 2018
Brian M. Culley [Member]
Number of shares available for grant			1,500,000
Exercise price per share			$ 2.31
Vesting percentage			25.00%
Brian M. Culley [Member] \| 2012 Equity Incentive Plan [Member] \| RSU Award No.1 [Member]
Number of restricted stock units grant			200,000
Vesting percentage			25.00%
Brian M. Culley [Member] \| 2012 Equity Incentive Plan [Member] \| RSU Award No.2 [Member]
Number of restricted stock units grant			100,000
Vesting date			Jan. 01, 2019

Stock-Based Awards - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) - 2012 Plan [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years	5 years 7 months 6 days
Risk-free interest rates	2.20%	2.80%
Volatility	63.10%	56.10%
Dividend yield	0.00%	0.00%

Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 3,580	$ 5,402
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	516	785
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 3,064	$ 4,617

Income Taxes (Details Narrative) - USD ($) $ in Thousands				12 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Nov. 28, 2018	Mar. 23, 2018	Feb. 17, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net income tax benefit				$ 7,400
Deferred tax assets, valuation allowance				59,596	$ 38,517	$ 7,400
Net operating loss carryforwards for federal tax purposes				164,000
Foreign net operating loss carryforwards				84,800
State net operating loss carryforwards				121,100
Repatriation tax foreign earnings in federal income						227
Net deferred tax assets						8,900
Proceeds from issuance of common stock				$ 103
Unrealized loss on deconsolidation of asterias					48,000
Net operating loss carryforwards change in ownership control				50.00%
Accrued interest and penalties
AgeX Therapeutics [Member]
Proceeds from issuance of common stock		$ 3,200
Gain on sale of equity method investment		3,200
Taxable gain	$ 26,400	2,200
Juvenescence Limited [Member]
Taxable gain		$ 29,400
OncoCyte Deconsolidation [Member]
Gain on deconsolidation of asterias			$ 71,700
Unrealized loss on deconsolidation of asterias						$ 2,900
Domestic [Member]
Net income tax benefit				$ 3,600	$ 300
Net operating losses expiration date				Between 2020 and 2039		Between 2027 and 2037
Tax credit carryforwards				$ 3,100
State Tax [Member]
Net income tax benefit				3,800
Net operating losses expiration date						Between 2030 and 2039
Tax credit carryforwards				5,500
Foreign [Member]
Net income tax benefit				$ 31
Maximum [Member]
Deferred tax assets and liabilities re-rated percentage						34.00%
Minimum [Member]
Deferred tax assets and liabilities re-rated percentage						21.00%

Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Loss before net income tax benefit	$ (19,234)	$ (47,130)
Domestic [Member]
Loss before net income tax benefit	(7,303)	(36,675)
Foreign [Member]
Loss before net income tax benefit	$ (11,931)	$ (10,455)

Income Taxes - Schedule of Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Computed tax benefit at federal statutory rate	21.00%	21.00%
Research and development and other credits	3.00%	1.00%
Removal of DTL for equity investment in Asterias due to merger	22.00%	0.00%
Permanent differences	(1.00%)	(3.00%)
Change in valuation allowance	(106.00%)	4.00%
Establish DTL for deferred assets from Asterias Merger	42.00%	0.00%
Establish DTL for AgeX/OncoCyte shares at deconsolidation	0.00%	8.00%
Deconsolidation of AgeX and subsidiaries net deferred tax assets	3.00%	(28.00%)
State tax benefit, net of effect on federal income taxes	54.00%	0.00%
Foreign rate differential	1.00%	(2.00%)
Income tax benefit	39.00%	1.00%

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 62,060	$ 37,761
Research and development and other credits	8,619	5,288
Patents and licenses	1,220	1,080
Stock options	2,708	2,062
Operating lease liability	832
Operating lease ROU assets	(775)
Equity method investments and marketable securities at fair value	(19,367)	(7,848)
Other, net	984	174
Total	56,281	38,517
Valuation allowance	(59,596)	(38,517)	$ (7,400)
Net deferred tax assets	$ (3,315)

Commitments and Contingencies (Details Narrative)								1 Months Ended				12 Months Ended
Commitments and Contingencies (Details Narrative)	Aug. 13, 2019 USD ($)	Jan. 28, 2019 USD ($)	Jan. 28, 2019 ILS (₪)	Jan. 05, 2019 USD ($)	Apr. 02, 2018 USD ($)	Apr. 02, 2018 ILS (₪)	Jan. 28, 2018 ft² m²	Aug. 31, 2019 USD ($)	May 31, 2019 ft²	Jan. 31, 2019 USD ($)	Dec. 31, 2015 ft² Subsidiary	Dec. 31, 2019 USD ($) ft² m²	Dec. 31, 2018 USD ($)	Aug. 01, 2019 USD ($) ft²	Feb. 01, 2019 USD ($)	Jan. 24, 2019 USD ($)	Dec. 31, 2018 ILS (₪)
Operating Leased Assets [Line Items]
Leasehold improvement construction in progress													$ 1,268,000
Cash fee												2,176,000	2,168,000
Access fees								$ 1,250,000
Amortized upfront payment fee												$ 2,500,000
Loss contingency, agreed-in-principle fee claim	$ 200,000
Royalty percentage												21.50%
Milestone aggregate amount												$ 3,500,000
Minimum annual maintenance fees												30,000
License fees and related expenses												47,000	$ 133,000
Minimum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees												135,000
Minimum [Member] \| Maintenance fees [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees												30,000
Maximum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees												150,000
Research and Option Agreement [Member] \| Orbit Biomedical Limited [Member]
Operating Leased Assets [Line Items]
Access fees payable				$ 2,500,000						$ 1,250,000		$ 1,250,000
Collaborative research activities description				The access fees payable by Lineage to Orbit for its technology and the injection device are $2.5 million in the aggregate, of which $1.25 million was paid in January 2019 upon execution of the Orbit Agreement and the remaining $1.25 million payment is due on the earlier of (i) six months from the Orbit Agreement date or, (ii) upon completion of certain collaborative research activities using the Orbit technology for the OpRegen Phase I/IIa clinical trial, as specified in the Orbit Agreement. In addition to the access fees, Lineage will pay Orbit for costs of consumables, training services, travel costs and other out of pocket expenses incurred by Orbit for performing services under the Orbit Agreement. Lineage has exclusive rights to the Orbit technology and its injection device for the treatment of dry-AMD during the term of the Orbit Agreement and may extend the term for an additional three months by paying Orbit a cash fee of $500,000.
Cash fee				$ 500,000
Cell Cure [Member]
Operating Leased Assets [Line Items]
Rent able area \| ft²							10,054
Lease, renewal term							5 years
Lease area \| m²							934
Base rent and construction allowance per month		$ 26,000
Cell Cure [Member] \| NIS [Member]
Operating Leased Assets [Line Items]
Base rent and construction allowance per month \| ₪			₪ 93,827
Office Space in New York City [Member]
Operating Leased Assets [Line Items]
Rent able area \| ft²												900
Base rent												$ 5,050
Future Years [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees												60,000
Carlsbad Lease [Member]
Operating Leased Assets [Line Items]
Rent able area \| ft²									8,841
Lease commencement date									Aug. 01, 2019
Lease expiration date									Oct. 31, 2022
Lease term									7 years
Alameda Lease [Member]
Operating Leased Assets [Line Items]
Rent able area \| ft²											30,795
Lease commencement date											Feb. 01, 2016
Lease expiration date											Jan. 31, 2023
Base rent														$ 17,850	$ 70,521
Base rent increase rate														3.00%	3.00%
Security deposit												78,000		$ 17,850	$ 424,000
Number of buildings for lease \| Subsidiary											2
Lease, renewal term											5 years
Lease term
Security deposit reduction in value																$ 78,000
Alameda Lease [Member] \| First Twenty-Four Months [Member]
Operating Leased Assets [Line Items]
Rent able area \| ft²														7,000
Office and Laboratory Space, Jerusalem, Israel [Member]
Operating Leased Assets [Line Items]
Base rent												$ 11,000
Construction allowances of leasehold improvements					$ 1,100,000
Office and Laboratory Space, Jerusalem, Israel [Member] \| NIS [Member]
Operating Leased Assets [Line Items]
Base rent \| ₪																	₪ 37,882
Construction allowances of leasehold improvements \| ₪						₪ 4,000,000
Office and Laboratory Space, Jerusalem, Israel [Member] \| Cell Cure [Member]
Operating Leased Assets [Line Items]
Rent able area \| ft²												7,842
Lease expiration date							Dec. 31, 2025						Dec. 31, 2020
Number of years lease can be extended													5 years
Lease area \| m²												728.5
Lease option to extend, description							Lease that expires on December 31, 2025, with two options to extend the lease for 5 years each (the "January 2018 Lease").
January 2018 Lease [Member]
Operating Leased Assets [Line Items]
Leasehold improvement construction in progress													$ 1,100,000
Deposit													$ 388,000

Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases	$ 1,364
Operating cash flows from financing leases	28
Financing cash flows from financing leases	30
Right of use assets obtained in exchange for lease obligations: Operating leases	738
Right of use assets obtained in exchange for lease obligations: Financing leases

Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Right-of-use assets, net	$ 775
Right-of-use lease liabilities, noncurrent	3,868	1,854
Total operating lease liabilities	832
Property and equipment, gross	96
Accumulated depreciation	(48)
Property and equipment, net	48
Current liabilities	33
Long-term liabilities	77	$ 104
Total finance lease liabilities	$ 110
Weighted average remaining lease term Operating leases	4 years 1 month 6 days
Weighted average remaining lease term Finance leases	3 years 4 months 24 days
Weighted average discount rate Operating leases	9.10%
Weighted average discount rate Finance leases	10.00%
Operating Lease Liability [Member]
Right-of-use assets, net	$ 4,666
Right-of-use lease liabilities, noncurrent	3,868
Total operating lease liabilities	5,058
Operating Lease Liability Current [Member]
Right-of-use lease liabilities, current	$ 1,190

Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Operating Leased Assets [Line Items]
Total	$ 832
2020	43
2021	36
2022	36
2023	15
2024
Thereafter
Total lease payments	130
Less imputed interest	(20)
Total	110
Operating Lease Liability [Member]
Operating Leased Assets [Line Items]
2020	1,590
2021	1,528
2022	1,508
2023	397
2024	308
Thereafter	811
Total lease payments	6,142
Less imputed interest	(1,084)
Total	$ 5,058

Segment Information (Details Narrative)	12 Months Ended
Segment Information (Details Narrative)	Dec. 31, 2019 Subsidiary
Segment Reporting [Abstract]
Number of operating segments	1

Enterprise-Wide Disclosures (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid expenses and other current assets	$ 2,863	$ 1,898
Royalties From Product Sales and License Fees [Member]
Prepaid expenses and other current assets	$ 800

Enterprise-Wide Disclosures - Schedule of Geographic Area Information (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

$ 3,515

$ 4,988

^[1],[2]

Long-lived assets

8,175

5,835

United States [Member]

2,092

1,804

^[1]

Foreign [Member]

^[3]

1,423

3,184

^[1]

Long-lived assets

^[4]

4,521

3,797

Domestic [Member]

Long-lived assets

$ 3,654

$ 2,038

[1]	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
[2]	These revenues were generated by LifeMap Sciences, which is a subsidiary of AgeX, are included in Lineage consolidated revenues for the period from January 1, 2018 through August 29, 2018, the date immediately preceding the AgeX Deconsolidation. As a result of the AgeX Deconsolidation on August 30, 2018, Lineage does not expect to recognize subscription and advertisement revenues during subsequent accounting periods.
[3]	Foreign revenues are primarily generated from grants in Israel.
[4]	Assets in foreign countries principally include laboratory equipment and leasehold improvements in Israel.

Enterprise-Wide Disclosures - Schedule of Revenues Disaggregated by Source (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

^[1]

$ 3,515

$ 4,988

^[2]

Grant Revenue [Member]

Royalties From Product Sales and License Fees [Member]

2,037

3,572

^[2]

Subscription and Advertisement Revenues [Member]

1,221

392

^[2]

Sale of Research Products and Services [Member]

^[3]

691